ClinicalTrialsFinder
RecruitingNCT06926192

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice

Sponsor

Peking Union Medical College

Enrollment

100 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Hidradenitis Suppurativa (HS)SecukinumabHidradenitis Suppurativa (Acne Inversa)

Summary

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Eligibility

Max Age: 80 Years

Inclusion Criteria4

  • Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
  • The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
  • Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
  • Patients with complete clinical data followed up for at least 1 year

Exclusion Criteria3

  • Patients lost to follow-up
  • Patients with less than one year of follow-up
  • Patients who received additional adjuvant therapy during the follow-up period
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTSurgery combined with secukinumab

Surgery combined with secukinumab

Locations(1)

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06926192

Related Trials

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT0728764433 locations

A Study With CIT-013 in HS Patients

NCT0699323324 locations

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT0721397327 locations

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498330 locations

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT0699361056 locations